ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Oral NONTOXIC Testosterone under review by FDA
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="PAUL-E" data-source="post: 40058" data-attributes="member: 13108"><p>I agree but there might be more of an effect on system at higher doses </p><p>"The most common drug-related adverse events over the 52 weeks for<strong> LPCN 1021 and testosterone gel </strong>were acne (2.9% vs 2.9%), headache (0.5% vs 3.8%), weight increase (2.4% vs 0.0%), hematocrit increase (1.9% vs 0.0%), <strong>liver enzyme level increase</strong> (1.4 % vs 0.0%), fatigue (0.5% vs 1.9%), and hypertension (0.5% vs 1.9%). Lipid parameters (cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides) were comparable in the two treatment groups at week 52. Changes in androgenic parameters from baseline to week 52 — such as hematocrit, hemoglobin, platelet, prothrombin, and prostate-specific antigen — were not significantly different between the two groups."</p><p></p><p>If it was effective I would imagine underground labs adapting the delivery system for their oral products</p></blockquote><p></p>
[QUOTE="PAUL-E, post: 40058, member: 13108"] I agree but there might be more of an effect on system at higher doses "The most common drug-related adverse events over the 52 weeks for[B] LPCN 1021 and testosterone gel [/B]were acne (2.9% vs 2.9%), headache (0.5% vs 3.8%), weight increase (2.4% vs 0.0%), hematocrit increase (1.9% vs 0.0%), [B]liver enzyme level increase[/B] (1.4 % vs 0.0%), fatigue (0.5% vs 1.9%), and hypertension (0.5% vs 1.9%). Lipid parameters (cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides) were comparable in the two treatment groups at week 52. Changes in androgenic parameters from baseline to week 52 — such as hematocrit, hemoglobin, platelet, prothrombin, and prostate-specific antigen — were not significantly different between the two groups." If it was effective I would imagine underground labs adapting the delivery system for their oral products [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Oral NONTOXIC Testosterone under review by FDA
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top